Overview
Antibody drug discovery driven by generative AI and digital biology
Funding
Amounts as reported; USD estimates shown only when they matchListed 3 funding records. Latest funding: $100M (Series B), Aug 11, 2026. Total raised (as reported): nearly $200M, as of Aug 11, 2026.
1 listed record lack a clear date or positive USD estimate for the chart.
| Date | Amount | Investors | Sources |
|---|---|---|---|
| Aug 11, 2026 | $100M · Series B | Granite Asia, Qiming Venture Capital, 弘晖基金, 纽尔利资本, 经纬创投 | 1 source Source ↗ |
Evidence Xunming Shengke raises USD 100 million in Series B funding, bringing total funding close to USD 200 millionOn 2026/8/11, Elsewhere reported that Chinese biological AI company Xunming Shengke raised USD 100 million in Series B funding, bringing total funding close to USD 200 million. The round was completed in stages, with proceeds supporting biological foundation model R&D and training at scale. Translated source brief, not a quotation. Check the original before citing. Sources · 1
| |||
| Apr 28, 2026 | $35M · Series A+ | Hongshan China, Qiming Venture Capital, 五源资本, 博远资本, 纽尔利资本, 经纬创投 | No source link |
Evidence Aureka Biotechnologies raises USD 35 million in Series A+ financingOn 2026-04-28, according to Xiniu Data, Aureka Biotechnologies completed Series A+ financing, raising USD 35 million. Investors were lead investor Hongshan China, Jingwei Venture Capital, Boyuan Capital, Wuyuan Capital and others. The company is a developer of antibody drugs using generative AI. Translated source brief, not a quotation. Check the original before citing. Sources · 0
Hongshan China, Qiming Venture Capital, 五源资本, 博远资本, 纽尔利资本, 经纬创投 | |||
| Nov 10, 2025 | Tens of millions of US dollars · Series A | Agentic Ventures, Qiming Venture Capital, 五源资本, 纽尔利资本 | No source link |
Evidence No source brief is attached to this record. Sources · 0
| |||
Select ▸ on a row to see its source brief and links.
Valuation
Amounts as reported; USD estimates shown only when they matchListed 3 valuation records.
No chartable valuation estimates yet.
3 listed records lack a clear date or positive USD estimate for the chart.
| Date | Amount | Investors | Sources |
|---|---|---|---|
| Aug 11, 2026 | — · Series B | Granite Asia, Qiming Venture Capital, 弘晖基金, 纽尔利资本, 经纬创投 | 1 source Source ↗ |
Evidence Xunming Shengke raises USD 100 million in Series B funding, bringing total funding close to USD 200 millionOn 2026/8/11, Elsewhere reported that Chinese biological AI company Xunming Shengke raised USD 100 million in Series B funding, bringing total funding close to USD 200 million. The round was completed in stages, with proceeds supporting biological foundation model R&D and training at scale. Translated source brief, not a quotation. Check the original before citing. Sources · 1
| |||
| Apr 28, 2026 | — · Series A+ | Hongshan China, Qiming Venture Capital, 五源资本, 博远资本, 纽尔利资本, 经纬创投 | No source link |
Evidence Aureka Biotechnologies raises USD 35 million in Series A+ financingOn 2026-04-28, according to Xiniu Data, Aureka Biotechnologies completed Series A+ financing, raising USD 35 million. Investors were lead investor Hongshan China, Jingwei Venture Capital, Boyuan Capital, Wuyuan Capital and others. The company is a developer of antibody drugs using generative AI. Translated source brief, not a quotation. Check the original before citing. Sources · 0
Hongshan China, Qiming Venture Capital, 五源资本, 博远资本, 纽尔利资本, 经纬创投 | |||
| Nov 10, 2025 | — · Series A | Agentic Ventures, Qiming Venture Capital, 五源资本, 纽尔利资本 | No source link |
Evidence No source brief is attached to this record. Sources · 0
| |||
Select ▸ on a row to see its source brief and links.
Revenue
Amounts as reported; USD estimates shown only when they matchListed 1 revenue record.
No chartable revenue estimates yet.
1 listed record lack a clear date or positive USD estimate for the chart.
| Revenue date | Amount | Sources |
|---|---|---|
| Aug 11, 2026 | 过去两年实现千万美元级商业收入 · Series B | 1 source Source ↗ |
Evidence Xunming Shengke raises USD 100 million in Series B funding, bringing total funding close to USD 200 millionOn 2026/8/11, Elsewhere reported that Chinese biological AI company Xunming Shengke raised USD 100 million in Series B funding, bringing total funding close to USD 200 million. The round was completed in stages, with proceeds supporting biological foundation model R&D and training at scale. Translated source brief, not a quotation. Check the original before citing. Sources · 1
| ||
Select ▸ on a row to see its source brief and links.
Team, products & investors
Sources · 0Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
No source links are available for this profile.
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
生成式 AI 与数字生物学驱动的抗体药物发现